| Name | Title | Contact Details |
|---|
Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.
Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.
Bioforward is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
biomarkerinc is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.